Patrick qualified as a chartered accountant with Deloitte Haskins & Sells before joining Cazenove & Co where he spent three years in the corporate finance department. He joined Close Brothers Group in 1989, where he was a director of the private equity and corporate finance divisions. He established Close Ventures in 1996 and led the management buyout to form Albion in 2009.
He has an MA in Modern Languages from Oxford University, and is on the board of the British Venture Capital Association, is a member of the audit committee of University College London and is a director of UCL Business, its technology transfer arm. Patrick is a Director of Albion Development VCT PLC and also Albion Community Power PLC.
Andrew initially practised as a surgeon for six years, specialising in neurosurgery, before joining the Boston Consulting Group (BCG) as a consultant in 2001. Whilst at BCG he specialised in healthcare strategy, gaining experience with many large, global clients across the full spectrum of healthcare including biotechnology, pharmaceuticals, service and care providers, software and telecommunications. Andrew now focuses on medical technologies, digital health and technology-enabled services to the life-science sector, and has served on the boards of companies ranging from diagnostics, imaging and software to pharmaceuticals and biomarkers. He has an MA plus Bachelors of Medicine and Surgery from Cambridge University and is a Fellow of the Royal College of Surgeons (England).
He joined Albion Capital in 2005 and became a partner in 2009. He has an MA plus Bachelors of Medicine and Surgery from Cambridge University and is a Fellow of the Royal College of Surgeons (England).
Simon manages the UCL Technology Fund, which is investing in commercialisation of life and physical sciences innovations from one of the most important academic institutions in the United Kingdom. He worked for seven and a half years at Goldman Sachs JBWere in Australia, predominantly on the Healthcare & Biotechnology and Portfolio Strategy teams, and has a PhD in neuroscience from the University of Cambridge.
David manages the UCL Technology Fund, which is investing in commercialisation of life and physical sciences innovations from one of the most important academic institutions in the United Kingdom. He previously worked for 4 years at Spark Impact, a subsidiary of Spark Ventures, investing across medical technology, telehealth and consumer healthcare. Before that he spent 3 years in China working in an FMCG start-up. David holds a Masters’ degree in Natural Science (Mathematics and Chemistry).
Ed began his career in investment banking, advising small and mid-cap public companies in the healthcare and technology sectors amongst others. After moving to Albion in 2004 (then part of Close Brothers Group), Ed started investing in the technology, healthcare, financial and business services sectors. Ed became partner in 2009 and is responsible for a number of Albion’s technology investments. Ed graduated from University College London with a first class degree in Philosophy.
Christoph joined Albion as an Investment Manager in October 2011 and focuses on investments in healthcare and renewables. He initially practised as a radiologist, before spending 3 years at Bain & Company. In 2006, he joined 3i working for their Healthcare Venture Capital arm. Most recently he has worked for General Electric's healthcare division, where he was responsible for mergers and acquisitions in the medical technology and healthcare IT sectors. He holds a degree in medicine from Ludwig-Maximilians University, Munich and an MBA from INSEAD.
Tanel joined the investment team at Albion Capital in 2018 having previously worked as an Investment Analyst at Newable Ventures. He completed his PhD at UCL where his was research focused on developing synthetic biological tools for microbiome engineering. Tanel also holds an MSc in Nanotechnology and Regenerative Medicine from UCL and a BSc in Human Biology from King’s College London.
Having trained as an accountant, after a spell at University of London Cengiz joined the Royal Free Hospital School of Medicine (RFHSM) in 1989. In 1993 he was appointed as Finance Director for RFHSM and then continued as Director of Financial and Business Affairs for the Medical School on its merger with UCL in 1998. Cengiz established Freemedic PLC (now UCL Business PLC (UCLB)) as the commercial arm of RFHSM in 1993 and formally transferred from his UCL role to the position of Managing Director for UCLB in 2004. Over the years he has been involved in many licences and spin-outs including PolyMASC Pharmaceuticals PLC, one of the first university spin-outs to float on the AIM in 1995, Medic to Medic Ltd (creators of the Map of Medicine) which was sold to Informa PLC in 2005 and Stanmore Implants Worldwide Limited which was acquired by Abingworth and MDY Healthcare in February 2008. Cengiz also acts as a Director for a number of UCLB’s spinout companies, including Pentraxin Therapeutics Limited, Evexar Medical Limited and the Bloomsbury BioSeed Fund as well as acting as advisor to a number of international technology transfer organisations and universities.
Anne has a PhD in medicine from UCL and an Executive MBA from Molson Business School, Montreal. After research at UCL and Harvard Medical School, Anne worked for RTP Pharma Inc in Montreal, out-licensing and preparing valuations of the company’s portfolio for public listing. Anne joined UCL Ventures in 2000 and acted as consultant for the National Transfer Centre in the US. She is now Executive Director of UCLB, acts as Director and interim CEO on several of UCLB’s spinout companies and oversees the company’s licensing activity. Anne is also a member of the Licensing Executives Society (LES) and is on the committee for the Intellectual Property Lawyers Organisation (TIPLO).
Steven brings extensive experience of licensing and spinout company creation to the UCLB team across areas ranging from ICT and petrochemicals through to medical devices and imaging. He is an engineer by training with a PhD in Process Control Engineering from Manchester Metropolitan University, which is complemented by industrial experience in the newspaper and process control industries and an Executive MBA from Manchester Business School. Steven is currently the Director of six UCL spinout companies and represents UCL’s interests in an IT-focused seed stage investment fund.
Rick is a cell and molecular biologist by training, gaining his PhD at McGill University, Canada. This was followed by a postdoctorate at the Imperial Cancer Research Fund, London, and then the National Institute for Medical Research. He left to join AstraZeneca as a team leader in the Department of Target Discovery, then worked for SanofiAventis as a Senior Team leader. In 2001 he left SanofiAventis and joined Impharmatica as Associate Director Target Discovery and worked very closely with the business development team. In 2006 he joined UCLB as Assistant Director BioPharm, becoming Director in 2007.
Dr Eliot Forster joined Immunocore as Chief Executive Officer in January 2015. He has almost 25 years of experience in the pharmaceutical and biotechnology industry. Dr Forster previously served as Chief Executive Officer of Creabilis since 2010 and prior to that role was Chief Executive Officer of US biotechnology company, Solace Pharmaceuticals Inc. His other previous roles include Head of EU Development and Operations for the EU and Asia at Pfizer, where he was responsible for drug development activities across multiple geographies and brought several drugs to market, and Clinical Research Manager at GlaxoSmithKline. Dr Forster is currently Chairman of the MedCity project that aims to grow a world-leading life sciences cluster in the south east of England. He holds a PhD in neurophysiology from Liverpool University and an MBA from Henley Management College.
Focus on investing in and working with tech startups, supplemented by teaching at business school. Former CEO of Priceline's non US operations, co-founder of Active Hotels (merged with bookings.org to form what is now Booking.com), former chairman of Toptable (now part of Priceline) and various other stuff.
Andy has an established track record in founding and scaling up innovative Biotech and Healthtech companies in the UK. He is currently Chairman of Arecor, Congenica, Abcodia, and the Babraham Research Campus and is a Director of Ieso Digital Health, Silence Therapeutics plc, Cancer Research Technology (commercial arm of CR-UK), Cambridge Temperature Concepts, and Cambridge University Hospitals NHS Foundation Trust. In addition to the UCL Technology Fund, he is an advisor to Cambridge Innovation Capital. His early career spanned positions with ICI (now AstraZeneca) and PA Technology, and he was a founder and executive director of Chiroscience plc. Since 1999 he has founded, invested in and helped to scale more than 25 innovative ventures including companies such as Vectura, Arakis, Cambridge Biotechnology Ltd and Geneservice. Andy is also a founder member of the Cambridge Angels and a trustee of the British Science Association.
Dr Robin Brown
Dr Robin Brown is currently the Chief Executive Officer at KWS BioTest, a specialist immunology-based CRO. He has also just been appointed as the new Chairman of Medicines Discovery Catapult as they move into the next phase of delivery alongside biotech and academia. Immediately before joining KWS, Robin spent eight years as a venture partner at Advent Healthcare Ventures and was responsible for a number of companies within the investment portfolio. Prior to this he was the Chief Scientific Officer of Devgen and Galapagos (EBR:DEVG, EBR:GLPG), both of which are now publically listed companies. Robin spent nine years at GSK, latterly as Head of Cell Biology and as an academic gained his PhD in the laboratory of Prof Alan Hall. He undertook postdoctoral work in the United States (Harvard) and London (Ludwig Institute).